Judge lifts YUTREPIA injunction; Tyvaso PH-ILD exclusivity expires March 31

Liquidia Corp

March 28: Judge Andrews set aside August 2022 injunction; FDA can now approve YUTREPIA NDA.
March 29: Judge Bates denied United Therapeutics' motion for TRO/preliminary injunction against FDA approval.
March 31: Regulatory exclusivity for Tyvaso in PH-ILD expired; FDA can act on YUTREPIA amended NDA.
United Therapeutics filed appeal and new lawsuits, but none currently block YUTREPIA launch.
Liquidia commercial team ready to launch for PAH and PH-ILD upon FDA final approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.